Reichman-Warmusz Edyta, Warmusz Oliwia, Wojnicz Romuald
Department of Histology and Cell Pathology in Zabrze, School of Medicine with the Division of Dentistry, Medical University of Silesia in Katowice, Jordana 19, 41-808 Zabrze, Poland.
Department of Histology and Cell Pathology in Zabrze, School of Medicine with the Division of Dentistry, Medical University of Silesia in Katowice, Zabrze, Poland.
Open Med (Wars). 2022 Jan 24;17(1):216-220. doi: 10.1515/med-2021-0374. eCollection 2022.
Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular weight heparin (LMWH) was associated with lower mortality in this cohort of patients. However, the timing of starting LMWH and the dose remain controversial in COVID-19 patients. Considering the above, the aim of this study was to reveal the rationale for using LMWH in the therapy of symptomatic COVID-19 patients based on experimental and clinical studies on LMWH in inflammatory settings with special consideration given to randomized trials.
越来越多的证据表明，2019年冠状病毒病（COVID-19）的不良结局与促血栓形成的微血管病变密切相关，静脉血栓栓塞风险很高。此外，首批观察性研究表明，在这类患者中，低分子量肝素（LMWH）辅助治疗与较低的死亡率相关。然而，在COVID-19患者中，开始使用LMWH的时机和剂量仍存在争议。考虑到上述情况，本研究的目的是基于在炎症环境中对LMWH进行的实验和临床研究，特别考虑随机试验，揭示在有症状的COVID-19患者治疗中使用LMWH的理论依据。
